Fig. 3From: Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in EnglandBox plots of pulmonary function (FVC [a] and FEV1 [b]) at baseline versus last follow-up in all patients (N = 40; mean follow-up 5.5 years). Lines show medians and first and third quartiles; asterisks show meansBack to article page